1,721,067 research outputs found
Pharmaceutical combinations comprising estrogen receptor-beta agonists with platinum drugs or paclitaxel for treating ovarian cancer
No full textfront page image
(EN)The invention provides a treatment of ovarian cancer, particularly ovarian cancer that is resistant to platinum-containing anti-cancer drugs, using an estrogen receptor β subtype (ERβ) agonist, wherein the treatment comprises administering the ERβ agonist to the patient, and administering a platinum-containing anti-cancer drug to the patient, the administrations being simultaneous, sequential or separate. The invention also provides an ERβ agonist and a platinum- containing anti-cancer drug for use in the treatment of ovarian cancer in a patient, wherein the treatment comprises administering the ERβ agonist to the patient, and administering the platinum-containing anti-cancer drug to the patient, the administrations being simultaneous, sequential or separate; a kit comprising an ERβ agonist, a platinum-containing anti-cancer drug, and a further compound suitable for the treatment of ovarian cancer; and an ERβ agonist for use in the treatment of ovarian cancer in a patient, or an ERβ agonist and a taxane for use in the treatment of ovarian cancer in a patient, wherein the treatment comprises administering the ERβ agonist to the patient, and administering a taxane to the patient, the administrations being simultaneous, sequential or separate.
(FR)L'invention concerne un traitement du cancer de l'ovaire, en particulier un cancer de l'ovaire qui est résistant aux médicaments anticancéreux contenant du platine, en utilisant un agoniste de récepteur des œstrogènes sous-type ß (ERβ), lequel traitement comprend l'administration de l'agoniste d'ERβ à la patiente, et l'administration d'un médicament anticancéreux contenant du platine à la patiente, les administrations étant simultanées, séquentielles ou séparées. L'invention concerne également un agoniste d'ERβ et un médicament anticancéreux contenant du platine destinés à être utilisés dans le traitement du cancer de l'ovaire chez une patiente, lequel traitement comprend l'administration de l'agoniste d'ERβ à la patiente, et l'administration du médicament anticancéreux contenant du platine à la patiente, les administrations étant simultanées, séquentielles ou séparées; un kit comprenant un agoniste d'ERβ, un médicament anticancéreux contenant du platine et un autre composé approprié au traitement du cancer de l'ovaire; et un agoniste d'ERβ destiné à être utilisé dans le traitement du cancer de l'ovaire chez une patiente, ou un agoniste d'ERβ et un taxane destinés à être utilisés dans le traitement du cancer de l'ovaire chez une patiente, lequel traitement comprend l'administration de l'agoniste d'ERβ à la patiente, et l'administration d'un taxane à la patiente, les administrations étant simultanées, séquentielles ou séparées
Expression and therapeutic significance of estrogen receptor beta (ERβ) in malignant pleural mesothelioma
No full text
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Variations on the Author
Full text link“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
Appropriate Similarity Measures for Author Cocitation Analysis
Full text linkWe provide a number of new insights into the methodological discussion about author cocitation analysis. We first argue that the use of the Pearson correlation for measuring the similarity between authors’ cocitation profiles is not very satisfactory. We then discuss what kind of similarity measures may be used as an alternative to the Pearson correlation. We consider three similarity measures in particular. One is the well-known cosine. The other two similarity measures have not been used before in the bibliometric literature. Finally, we show by means of an example that our findings have a high practical relevance.information science;Pearson correlation;cosine;similarity measure;author cocitation analysis
Phenotypic correction of the defective fibronectin extracellular matrix of Elhers-Danlos syndrome fibroblasts
No full text8-Prenylnaringenin inhibits estrogen receptor-alpha mediated cell growth and induces apoptosis in MCF-7 breast cancer cells
No full textDispelling the Myths Behind First-author Citation Counts
Full text linkWe conducted a full-scale evaluative citation analysis study of scholars in the XML research field to explore just how different from each other author rankings resulting from different citation counting methods actually are, and to demonstrate the capability of emerging data and tools on the Web in supporting more realistic citation counting methods. Our results contest some common arguments for the continued
use of first-author citation counts in the evaluation of scholars, such as high correlations between author rankings by first-author citation counts and other citation
counting methods, and high costs of using more realistic citation counting methods that are not well-supported by the ISI databases. It is argued that increasingly available digital full text research papers make it possible for citation analysis studies to go beyond what the ISI databases have directly supported and to employ more
sophisticated methods
- …
